De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ACOR.Q Overzicht aandelen
A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Acorda Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.02 |
| 52 Week Hoogtepunt | US$18.00 |
| 52 Week Laag | US$0.013 |
| Bèta | 1.69 |
| 11 maand verandering | -84.62% |
| 3 maanden verandering | -96.88% |
| 1 Jaar Verandering | -99.88% |
| 33 jaar verandering | -99.97% |
| 5 jaar verandering | -99.99% |
| Verandering sinds IPO | -100.00% |
Recent nieuws en updates
Recent updates
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?
Feb 21
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement
Dec 18Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?
Jun 05Acorda wins $16.5M in Ampyra arbitration case with Alkermes
Oct 17Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote
Oct 10Acorda inks license deal with Asieris for pre-clinical drug
Aug 29Acorda Therapeutics announces resignation of COO
Aug 19Acorda Therapeutics: Managing The Transition
Oct 04Acorda Therapeutics Continues To Maneuver For A Turnaround
Jul 24CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Jun 17Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now
May 26Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts
Mar 09Rendement voor aandeelhouders
| ACOR.Q | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -28.5% | 0.6% | 0.8% |
| 1Y | -99.9% | 27.4% | 38.3% |
Rendement versus industrie: ACOR.Q underperformed the US Biotechs industry which returned 9.2% over the past year.
Rendement versus markt: ACOR.Q underperformed the US Market which returned 16.9% over the past year.
Prijsvolatiliteit
| ACOR.Q volatility | |
|---|---|
| ACOR.Q Average Weekly Movement | 55.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: ACOR.Q's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ACOR.Q's weekly volatility has increased from 34% to 56% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1995 | 102 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc. Samenvatting
| ACOR.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$37.39k |
| Inkomsten(TTM) | -US$263.42m |
| Inkomsten(TTM) | US$115.66m |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs ACOR.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ACOR.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$115.66m |
| Kosten van inkomsten | US$20.48m |
| Brutowinst | US$95.19m |
| Overige uitgaven | US$358.61m |
| Inkomsten | -US$263.42m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -212.08 |
| Brutomarge | 82.30% |
| Nettowinstmarge | -227.75% |
| Schuld/Eigen Vermogen Verhouding | -103.1% |
Hoe presteerde ACOR.Q op de lange termijn?
Bekijk historische prestaties en vergelijking